Skip to main content
. Author manuscript; available in PMC: 2014 Dec 12.
Published in final edited form as: Lung Cancer. 2013 Apr 21;81(1):47–52. doi: 10.1016/j.lungcan.2013.03.018

Table 4.

E1594: Median Progression Free Survival According to Histology and Chemotherapy Regimens

Regimens Histology
Squamous Cell
Carcinoma
n = 224		 Adenocarcinoma
n = 647		 Large Cell
Carcinoma
n = 74		 Others/Not
Otherwise
Specified
n = 194
Cisplatin-Paclitaxel - mo (95% CI) 2.6 (1.7-4.2) 3.7 (3.1-4.3) 3.5 (1.4-∞) 2.8 (1.8-4.0)
Cisplatin-Gemcitabine - mo (95% CI) 4.3 (3.3-6.6) 4.4 (3.8-5.4) 4.5 (2.0-11.5) 3.4 (2.8-5.1)
Cisplatin-Docetaxel - mo (95% CI) 3.1 (2.4-5.0) 3.7 (2.6-4.6) 4.2 (2.9-6.6) 3.6 (2.7-5.6)
Carboplatin-Paclitaxel - mo (95% CI) 3.7 (3.0-5.0) 3.5 (2.9-4.2) 3.9 (1.9-7.8) 2.2 (1.7-3.9)

CI, confidence interval